88 related articles for article (PubMed ID: 32940815)
41. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
[TBL] [Abstract][Full Text] [Related]
42. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
Tantai J; Hu D; Yang Y; Geng J
Int J Clin Exp Pathol; 2015; 8(7):7887-95. PubMed ID: 26339353
[TBL] [Abstract][Full Text] [Related]
43. Accuracy of volatile urine biomarkers for the detection and characterization of lung cancer.
Mazzone PJ; Wang XF; Lim S; Choi H; Jett J; Vachani A; Zhang Q; Beukemann M; Seeley M; Martino R; Rhodes P
BMC Cancer; 2015 Dec; 15():1001. PubMed ID: 26698840
[TBL] [Abstract][Full Text] [Related]
44. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
45. Screening and staging for non-small cell lung cancer by serum laser Raman spectroscopy.
Wang H; Zhang S; Wan L; Sun H; Tan J; Su Q
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Aug; 201():34-38. PubMed ID: 29729529
[TBL] [Abstract][Full Text] [Related]
46. Dramatically changed immune-related molecules as early diagnostic biomarkers of non-small cell lung cancer.
Ye X; Zhang N; Jin Y; Xu B; Guo C; Wang X; Su Y; Yang Q; Song J; Yu W; Cheng P; Cheng L; Gong Y; Fu X; Sun H
FEBS J; 2020 Feb; 287(4):783-799. PubMed ID: 31482685
[TBL] [Abstract][Full Text] [Related]
47. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
48. Simple and micro high-performance liquid chromatographic method for simultaneous determination of p-aminohippuric acid and iothalamate in biological fluids.
Prueksaritanont T; Chen ML; Chiou WL
J Chromatogr; 1984 Mar; 306():89-97. PubMed ID: 6609166
[TBL] [Abstract][Full Text] [Related]
49. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
50. GM2-activator protein: a new biomarker for lung cancer.
Potprommanee L; Ma HT; Shank L; Juan YH; Liao WY; Chen ST; Yu CJ
J Thorac Oncol; 2015 Jan; 10(1):102-9. PubMed ID: 25490003
[TBL] [Abstract][Full Text] [Related]
51. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease.
Deja S; Porebska I; Kowal A; Zabek A; Barg W; Pawelczyk K; Stanimirova I; Daszykowski M; Korzeniewska A; Jankowska R; Mlynarz P
J Pharm Biomed Anal; 2014 Nov; 100():369-380. PubMed ID: 25213261
[TBL] [Abstract][Full Text] [Related]
52. Preoperative diagnosis of malignant pulmonary nodules in lung cancer screening with a radiomics nomogram.
Liu A; Wang Z; Yang Y; Wang J; Dai X; Wang L; Lu Y; Xue F
Cancer Commun (Lond); 2020 Jan; 40(1):16-24. PubMed ID: 32125097
[TBL] [Abstract][Full Text] [Related]
53. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer.
Leyten GH; Hessels D; Smit FP; Jannink SA; de Jong H; Melchers WJ; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Schalken JA
Clin Cancer Res; 2015 Jul; 21(13):3061-70. PubMed ID: 25788493
[TBL] [Abstract][Full Text] [Related]
54. Blood test shows high accuracy in detecting stage I non-small cell lung cancer.
Goebel C; Louden CL; Mckenna R; Onugha O; Wachtel A; Long T
BMC Cancer; 2020 Feb; 20(1):137. PubMed ID: 32085733
[TBL] [Abstract][Full Text] [Related]
55. A metabolomic approach to lung cancer.
Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
[TBL] [Abstract][Full Text] [Related]
56. Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics.
Klupczynska A; Dereziński P; Garrett TJ; Rubio VY; Dyszkiewicz W; Kasprzyk M; Kokot ZJ
J Cancer Res Clin Oncol; 2017 Apr; 143(4):649-659. PubMed ID: 28168355
[TBL] [Abstract][Full Text] [Related]
57. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer.
Yoshimura M; Nishimura R; Murotani A; Miyamoto Y; Nakagawa T; Hasegawa K; Koizumi T; Shii K; Baba S; Tsubota N
Cancer; 1994 Jun; 73(11):2745-52. PubMed ID: 7514953
[TBL] [Abstract][Full Text] [Related]
58. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
59. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
60. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
